MARKET

EVMN

EVMN

EVOMMUNE INC
NYSE
8.35
-0.04
-0.48%
Closed 19:30 09/29 EDT
OPEN
8.36
PREV CLOSE
8.39
HIGH
8.65
LOW
8.11
VOLUME
807.60K
TURNOVER
--
52 WEEK HIGH
33.20
52 WEEK LOW
8.11
MARKET CAP
303.04M
P/E (TTM)
-5.4358
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EVMN last week (0921-0925)?
Weekly Report · 1d ago
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
TipRanks · 6d ago
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Benzinga · 6d ago
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301
Seeking Alpha · 09/22 10:05
Weekly Report: what happened at EVMN last week (0914-0918)?
Weekly Report · 09/21 10:28
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF)
TipRanks · 09/18 11:50
Evommune updates pipeline and market outlook in presentation
TipRanks · 09/15 13:00
Weekly Report: what happened at EVMN last week (0907-0911)?
Weekly Report · 09/14 10:34
More
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Webull offers Evommune, Inc. stock information, including NYSE: EVMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVMN stock methods without spending real money on the virtual paper trading platform.